Chief Business Officer of Medace Kurt Gielen recently wrote this interesting perspective article together with Joshua Hunsberger and several co-authors, now published at Stem Cells Translational Medicine: 

Kurt Gielen: I’d like to contribute to ensuring a smooth transition of regenerative medicine therapies to market, by supporting the professionalisation of this industry.’

 

Stem Cells cover

‘Improving patient outcomes with regenerative medicine’: 

How the Regenerative Medicine Manufacturing Society plans to move the needle forward in cell manufacturing, standards, 3D bioprinting, artificial intelligence‐enabled automation, education, and training.

Read the full article here.